Drug profile · INN
aprotinin
TRASYLOL
aprotinin (TRASYLOL) is a plasminogen inhibitor. Route of administration: injection. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — aprotinin
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
aprotinin (TRASYLOL) is a plasminogen inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN aprotinin
Brand TRASYLOL
Mechanism Plasminogen inhibitor
Target Plasma kallikrein
Route INJECTION
Formulation INJECTABLE
Mechanism of action
Plasminogen inhibitor
Primary target: Plasma kallikrein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is aprotinin?
aprotinin (TRASYLOL) is a plasminogen inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for aprotinin?
TRASYLOL is a marketed brand name for aprotinin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aprotinin?
aprotinin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.